Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

670 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.
Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel AB, Diefenbach C. Carreau NA, et al. Among authors: david k. Oncologist. 2020 Oct;25(10):878-885. doi: 10.1634/theoncologist.2020-0167. Epub 2020 Aug 28. Oncologist. 2020. PMID: 32720734 Free PMC article.
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ. Ayers EC, et al. Among authors: david ka. Cancer. 2020 Jan 15;126(2):293-303. doi: 10.1002/cncr.32526. Epub 2019 Sep 30. Cancer. 2020. PMID: 31568564 Free article.
Management of older Hodgkin lymphoma patients.
Evens AM, Carter J, Loh KP, David KA. Evens AM, et al. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):233-242. doi: 10.1182/hematology.2019000028. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808898 Free PMC article.
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, Armand P. Merryman RW, et al. Among authors: david ka. Oncologist. 2020 Jun;25(6):e993-e997. doi: 10.1634/theoncologist.2020-0040. Epub 2020 Apr 28. Oncologist. 2020. PMID: 32275786 Free PMC article.
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C. Carreau NA, et al. Among authors: david k. Br J Haematol. 2020 Oct;191(1):44-51. doi: 10.1111/bjh.16756. Epub 2020 May 19. Br J Haematol. 2020. PMID: 32430944 Free article.
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein AK, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Ramdial J, Maliske SM, Epperla N, Venugopal P, Feldman TA, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning MA, Caimi P, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP. Evens AM, et al. Among authors: david ka. Blood. 2021 Jan 21;137(3):374-386. doi: 10.1182/blood.2020006926. Blood. 2021. PMID: 32663292 Free PMC article.
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Sharon E, Streicher H, Kahl BS, Ansell SM. Diefenbach CS, et al. Among authors: david ka. Lancet Haematol. 2020 Sep;7(9):e660-e670. doi: 10.1016/S2352-3026(20)30221-0. Lancet Haematol. 2020. PMID: 32853585 Free PMC article. Clinical Trial.
Burkitt Lymphoma International Prognostic Index.
Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, El-Galaly TC, Evens AM. Olszewski AJ, et al. Among authors: david ka. J Clin Oncol. 2021 Apr 1;39(10):1129-1138. doi: 10.1200/JCO.20.03288. Epub 2021 Jan 27. J Clin Oncol. 2021. PMID: 33502927 Free PMC article.
670 results